Resetting Severe Allergies at Their Cellular Source

Episode Summary

Executive Summary: Sid Kirkar of Allergene AI Therapeutics argues that severe allergies and mast cell diseases need a root-cause therapy, not lifelong symptom control. The company is developing an in vivo mRNA CAR T approach delivered by targeted lipid nanoparticles to transiently program T cells to eliminate mast cells, aiming to reset immunity and repopulate with less reactive cells.

Main Topics: Limitations of current allergy and mast cell treatments (Priority: 5/5): Existing therapies mostly manage symptoms or reduce reaction risk, but do not address the underlying disease biology. Patients often live with continuous treatment and persistent fear of anaphylaxis. Mast cells as the disease driver (Priority: 5/5): Kirkar explains that mast cells are tissue-resident immune cells in the gut, lungs, and skin that can be sensitized to food, stings, drugs, and other triggers, making them central to severe allergic disease. In vivo mRNA CAR T platform (Priority: 5/5): Allergene AI’s approach uses lipid nanoparticles to deliver mRNA to T cells, temporarily expressing a CAR on the cells in the body so they can seek out and eliminate mast cells without permanent genome editing. Immune reset and repopulation (Priority: 4/5): Rather than permanently depleting all mast cells, the strategy aims to remove sensitized/pathogenic populations and allow new mast cells to repopulate in a less reactive state while preserving normal immune functions. Why mast-cell targeting differs from existing therapies (Priority: 4/5): Current approaches focus on IgE, histamine, or broader signaling pathways such as KIT; Allergene argues its method is more direct and more specific because it targets a mast-cell-selective marker with CAR T cells. Development path, scalability, and AI (Priority: 3/5): The company is still in early R&D, using AI for literature review, target validation, and data integration, while emphasizing that mRNA/LNP manufacturing and storage could make the therapy more scalable than traditional cell therapies. Funding and commercialization strategy (Priority: 3/5): Allergene is currently funded through angels and non-dilutive sources, with plans to approach institutional investors once preclinical data de-risks the platform and supports clinical entry.

Key Arguments: Severe allergies remain a chronic, lifelong-management problem because current drugs mainly suppress symptoms or lower reaction likelihood rather than cure the disease. Mast cells are the key effector cells in these diseases, so directly eliminating sensitized mast cells could reset the immune system instead of treating downstream consequences. An in vivo mRNA CAR T strategy may be safer and more flexible than permanent gene editing because the CAR expression is transient and can be dose-adjusted or repeated. Targeted lipid nanoparticles can deliver mRNA to T cells in vivo, potentially making CAR T more scalable, off-the-shelf, and easier to distribute than ex vivo engineered products. A mast-cell-specific target could offer greater precision than KIT- or IgE-based strategies, which may affect broader cell populations or only modulate the pathway indirectly. The platform is intended first for severe mast cell diseases such as mastocytosis and chronic urticaria, with possible expansion to anaphylaxis, food allergy, and allergic asthma. AI is used to accelerate target discovery, normal-tissue risk assessment, and integration of public and proprietary data, improving R&D efficiency and candidate selection.

Data Points: CAR expression duration: 7 to 10 days - Sid Kirkar said the mRNA-expressed CAR is intended to be active long enough to do its job, then disappear without permanent integration. Single-cell analysis sources: 1,700 publications - Kirkar described using AI to analyze data across 1,700 publications for target validation and tissue-expression questions. Lead indications: 2 - The company’s first clinical focus is on mastocytosis and chronic urticaria. Funding categories: 3 - Kirkar said the company has raised from angel investors, has non-dilutive funding, and plans to move to institutional investors later.

Pivotal Quotes: "Fear is the number one daily aspect that these patients suffer from." — Sid Kirkar: He described the psychological burden of living with severe allergies and the constant risk of accidental exposure. "What we want to do is reset those cells and eliminate those cells. That causes the disease, and then have new ones repopulate that are not sensitized." — Sid Kirkar: He summarized the therapeutic goal of removing pathogenic mast cells and allowing a less reactive immune population to rebuild. "The same concepts can apply to mast cells... We want to do is reset those cells and eliminate those cells." — Sid Kirkar: He connected prior oncology/autoimmune immune-reset concepts to allergy and mast cell disease.

Implications: If successful, this platform could shift severe allergy care from chronic suppression to disease modification, potentially improving safety, convenience, and access. It also broadens in vivo CAR T beyond cancer and autoimmune disease into allergy.